Mostrar registro simples

dc.contributor.authorSilva, Nadia Regina Jardim dapt_BR
dc.contributor.authorLaste, Gabrielapt_BR
dc.contributor.authorDeitos, Alíciapt_BR
dc.contributor.authorStefani, Luciana Paula Cadorept_BR
dc.contributor.authorCanto, Gustavo Cambraia dopt_BR
dc.contributor.authorTorres, Iraci Lucena da Silvapt_BR
dc.contributor.authorBrunoni, Andre Russowskypt_BR
dc.contributor.authorFregni, Felipept_BR
dc.contributor.authorCaumo, Wolneipt_BR
dc.date.accessioned2019-01-16T04:09:52Zpt_BR
dc.date.issued2015pt_BR
dc.identifier.issn1662-5153pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/187803pt_BR
dc.description.abstractTranscranial direct current stimulation (tDCS) and melatonin can effectively treat pain. Given their potentially complementary mechanisms of action, their combination could have a synergistic effect. Thus, we tested the hypothesis that compared to the control condition and melatonin alone, tDCS combined with melatonin would have a greater effect on pain modulatory effect, as assessed by quantitative sensory testing (QST) and by the pain level during the Conditioned Pain Modulation (CPM)-task. Furthermore, the combined treatment would have a greater cortical excitability effect as indicated by the transcranial magnetic stimulation (TMS) and on the serum BDNF level. Healthy males (n = 20), (aged 18–40 years), in a blinded, placebo-controlled, crossover, clinical trial, were randomized into three groups: sublingual melatonin (0.25 mg/kg) + a-tDCS, melatonin (0.25 mg/kg) + sham-(s)-tDCS, or sublingual placebo+sham-(s)- tDCS. Anodal stimulation (2 mA, 20 min) was applied over the primary motor cortex. There was a significant difference in the heat pain threshold ( C) for melatonin+a-tDCS vs. placebo+s-tDCS (mean difference: 4.86, 95% confidence interval [CI]: 0.9 to 8.63) and melatonin+s-tDCS vs. placebo+s-tDCS (mean: 5.16, 95% CI: 0.84 to 8.36). There was no difference between melatonin+s-tDCS and melatonin+a-tDCS (mean difference: 0.29, 95% CI: 􀀀3.72 to 4.23). The mean change from the baseline on amplitude of motor evocate potential (MEP) was significantly higher in the melatonin+a-tDCS (􀀀19.96% 5.2) compared with melatonin+s-tDCS group (􀀀1.36% 5.35) and with placebo+s-tDCS group (3.61% 10.48), respectively (p < 0.05 for both comparisons). While melatonin alone or combined with a-tDCS did not significantly affect CPM task result, and serum BDNF level. The melatonin effectively reduced pain; however, its association with a-tDCS did not present an additional modulatory effect on acute induced pain.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofFrontiers in behavioral neuroscience. Lausanne. Vol. 9 (Mar. 2015), article 77, [12] p.pt_BR
dc.rightsOpen Accessen
dc.subjecttDCSen
dc.subjectEstimulação magnética transcranianapt_BR
dc.subjectTMSen
dc.subjectLimiar da dorpt_BR
dc.subjectCPMen
dc.subjectMelatoninapt_BR
dc.subjectEnsaio clínicopt_BR
dc.subjectPain thresholden
dc.subjectMelatoninen
dc.subjectClinical trialen
dc.titleCombined neuromodulatory interventions in acute experimental pain : assessment of melatonin and non-invasive brain stimulationpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb000956682pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples